Nabriva Therapeutics plc - NBRV STOCK NEWS

Nabriva Therapeutics (NBRV) reported Q1 2022 results, showcasing a revenue increase to $8.0 million, up from $2.5 million in Q1 2021, driven primarily by $7.2 million in SIVEXTRO sales. The company extended its distribution agreement with Merck for SIVEXTRO through 2026 and saw a 10% growth in prescription demand. However, the net loss for the quarter was $11.8 million, down from $14.0 million the previous year. Nabriva has $33.8 million in cash, adequate for operations into Q4 2022.

Nabriva Therapeutics (NASDAQ: NBRV) has extended its exclusive agreement with Merck to promote and distribute SIVEXTRO (tedizolid phosphate) in the U.S. until December 31, 2026. Initially signed in July 2020, the agreement now provides for a longer partnership, potentially extending for an additional three years upon mutual consent. SIVEXTRO is approved for treating acute bacterial skin infections in adults and pediatric patients. The CEO expressed enthusiasm for the extension, emphasizing its potential to contribute to Nabriva's long-term growth.

Nabriva Therapeutics (NASDAQ: NBRV) plans to release its first-quarter financial results on May 5, 2022, after U.S. markets close. The company, known for developing innovative anti-infective agents, has received FDA approval for XENLETA and has partnered with Merck to distribute SIVEXTRO in the U.S. A conference call will be held at 4:30 p.m. ET to discuss the results and company highlights. The dial-in details are provided for both domestic and international participants, along with a live webcast option.

Nabriva Therapeutics (NASDAQ: NBRV) announced the enrollment of the first patient in a Phase 1 clinical trial evaluating the safety and pharmacokinetics of oral and intravenous XENLETA (lefamulin) in adults with cystic fibrosis (CF). This trial addresses the challenge of treating S. aureus infections, particularly MRSA, in CF patients, which can significantly reduce survival rates. XENLETA is positioned as a novel treatment option due to its potential to offer a well-tolerated solution for MRSA.

Nabriva Therapeutics reported total revenue of $9.3 million for Q4 2021, driven by an 8% sequential increase in net product sales. SIVEXTRO prescriptions grew by 5% year-over-year. The company's cash runway has been extended into Q4 2022, with a net loss reduced to $13.1 million from $17.8 million in Q4 2020. For the entire year, revenues reached $28.9 million, compared to $5.0 million the previous year. The decrease in operational costs contributed to improved financial stability. Management remains focused on expanding SIVEXTRO and XENLETA.

Nabriva Therapeutics plc (NASDAQ: NBRV) announced that it will report its financial results for Q4 and full year 2021 on March 29, 2022, after U.S. market close. The conference call is scheduled for 4:30 p.m. ET to discuss these results and recent corporate highlights. Nabriva is known for its innovative anti-infective agents, including XENLETA for community-acquired bacterial pneumonia. The company is also developing CONTEPO for complicated urinary tract infections and has partnered with Merck to market SIVEXTRO in the U.S.

Nabriva Therapeutics plc (NASDAQ: NBRV) announced a non-statutory stock option for 12,000 ordinary shares, granted to a new employee as part of their compensation. The option, effective February 28, 2022, has an exercise price of $0.45 per share, equaling the closing price on that date. It features a 10-year term, vesting over four years at 25% annually, contingent on continued employment. This grant complies with Nasdaq’s inducement grant exception. Nabriva is focused on anti-infective agents, with FDA approval for XENLETA and ongoing development of CONTEPO.

Nabriva Therapeutics (NASDAQ: NBRV) announced the adjournment of its extraordinary general meeting of shareholders (EGM) without conducting business on January 18, 2022. The meeting will reconvene on March 24, 2022, to secure additional proxies for a proposal outlined in its proxy statement filed on November 22, 2021. The new record date for determining shareholder eligibility to vote is February 18, 2022. Shareholders can vote via proxy, telephone, or Internet as outlined in the upcoming proxy card.

Nabriva Therapeutics has adjourned its extraordinary general meeting (EGM) scheduled for January 14, 2022, to gather additional shareholder proxies for a proposal outlined in its proxy statement from November 22, 2021. The EGM will reconvene on January 18, 2022, at 7:00 p.m. Irish time. Shareholders can vote online, by phone, mail, or in person. Proxies submitted prior to the adjournment will remain valid unless revoked. The company is known for its anti-infective agents, having received FDA approval for XENLETA and is developing CONTEPO.